Chair's Vision Statement and Data-to-Clinic Translational Summary

Chair's Vision Statement and Data-to-Clinic Translational Summary

Which Patients with Advanced CSCC Will Likely Benefit Most from PD1Checkpoint Inhibition? A Best Practice, Evidence?Supported Roadmap for Dermatology Specialist


Published

December 26, 2018

Created by

CMEducation Resources symposium

Related Presenters

Darrell Rigel, MS, MD

Darrell Rigel, MS, MD

Program ChairClinical Professor of DermatologyNew York Medical CenterNew York, NY